We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis
Effectiveness and Safety of Tirzepatide Compared to GLP-1 Receptor Agonists in People with Type 2 Diabetes Using Basal Insulin
AI simplified
Abstract
Tirzepatide 5, 10, and 15 mg resulted in statistically significant greater reductions in and body weight compared to all GLP-1 RA comparators and placebo.
- Tirzepatide demonstrated greater changes in glycated haemoglobin (HbA1c) levels and body weight at the primary endpoint compared to GLP-1 receptor agonists and placebo.
- Patients receiving tirzepatide had a statistically significant higher likelihood of experiencing nausea compared to those on placebo or exenatide 2 mg.
- No significant differences were observed in treatment discontinuation due to adverse events when comparing tirzepatide with GLP-1 RA comparators, except for tirzepatide 10 and 15 mg versus placebo.
- The overall safety profile of tirzepatide was similar to that of GLP-1 receptor agonists.
AI simplified
Key numbers
14.8×
Increase in likelihood of achieving < 7.0%
Likelihood of achieving < 7.0% with vs. lixisenatide.
0.86%
Reduction in
Change from baseline in with .
6.1
Proportion of patients experiencing nausea
Proportion experiencing nausea with 15 mg vs. .